Werschnik C, Lommatzsch P K
Klin Monbl Augenheilkd. 1998 Jun;212(6):465-8. doi: 10.1055/s-2008-1034931.
Since 1995 we have used Mitomycin C additionally in the treatment of conjunctival melanoma and primary acquired melanosis.
We report on the therapy results of 14 patients suffering from pigmented conjunctival lesions (malignant melanoma 9 and primary acquired melanosis 5). After local excision, cryotherapy or irradiation all patients received one eye drop Mitomycin C (0.02%) four times daily for four to six weeks.
We observed regression of the pigmentations in 11 cases after median follow up of 13.1 months. In one patient there was no change. Two cases showed progression with tumefaction. There were no adverse reactions except conjunctival hyperemia during therapy.
Topical administration of Mitomycin C may be useful in the treatment of pigmented conjunctival lesions. Longer follow-up periods are necessary.
自1995年以来，我们额外使用丝裂霉素C治疗结膜黑色素瘤和原发性后天性黑变病。
我们报告了14例患有色素性结膜病变（恶性黑色素瘤9例，原发性后天性黑变病5例）患者的治疗结果。在局部切除、冷冻疗法或放射治疗后，所有患者每天四次滴用丝裂霉素C眼药水（0.02%），持续四至六周。
在中位随访13.1个月后，我们观察到11例患者色素沉着消退。1例患者无变化。2例出现进展并伴有肿胀。治疗期间除结膜充血外无不良反应。
局部应用丝裂霉素C可能对色素性结膜病变的治疗有用。需要更长的随访期。
